The firm’s first fund dedicated to biotech and biopharmaceuticals.
Jeito Capital is a leading global investment company. Jeito was founded and directed by Dr. Rafaèle Tordjman, a hematologist and former fellow in Paris University Hospitals and research scientist at INSERM, who has been an investor in life sciences for more than 20 years.
Jeito I has raised 534 million euros.
In its first 18 months, Jeito Capital has built a solid and diverse portfolio of European biotechnology companies. Jeito has invested in French companies SparingVision, in the field of ophthalmology, and InnoSkel, in rare skeletal disorders, as well as Dutch biotech Neogene Therapeutics offering new options for solid tumors, U.K.-based Pulmocide, for severe respiratory diseases, and recently the French-Swiss Alentis Therapeutics in the treatment of fibrosis and associated cancers.
Further with the entrepreneur